Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?

BMC Medicine

Minireview

Jordi Remon¹  Benjamin Besse²  Jean-Charles Soria³ 

[1] Cancer Medicine Department, Gustave Roussy, Villejuif, France;Medical Oncology Department, Hospital Vall d’Hebron, Barcelona, Spain;Cancer Medicine Department, Gustave Roussy, Villejuif, France;University Paris-Sud, Orsay, France;University Paris-Sud, Orsay, France;

关键词: Immunotherapy;    Pembrolizumab;    Nivolumab;    PD-1;    PD-L1;    First-line;    Non-small cell lung cancer;   

DOI  :  10.1186/s12916-017-0819-3

 received in 2017-01-03, accepted in 2017-02-16,  发布年份 2017

来源: Springer

【 摘 要 】

Immune checkpoint inhibitors have significantly modified the therapeutic landscape of advanced non-small cell lung cancer in second-line settings, with a more recent advancement in first-line settings. Given the superior outcome with pembrolizumab as an upfront strategy, PD-L1 status should now be considered a new reflex biomarker to guide first-line treatment in patients with advanced non-small cell lung cancer. Improved responses have also been reported with the combination of immune checkpoint inhibitors and chemotherapy as the first-line treatment; however, this strategy has not yet been validated by phase III trial data and its interplay with PD-L1 status still requires clarification.Herein, we review the contradictory results of recent phase III trials with immune checkpoint inhibitors in the first-line setting, the potential reasons for such discrepancies, and some of the remaining points of discussion related to the positioning of immune checkpoint inhibitors in the first-line therapy of non-small cell lung cancer.

【 授权许可】

CC BY   
© The Author(s). 2017